$PAOG - Nice News!! PAOG Cannabis Pharmaceutical Research Initiative Gains New Traction
Sandusky, Ohio--(Newsfile Corp. - September 30, 2020) - PAO Group, Inc. (OTC Pink: PAOG) today indicated plans to reveal new information on the Company's initiative to expand its cannabis pharmaceutical treatment research beyond its current focus on Chronic Obstructive Pulmonary Disease (COPD).
In a media interview scheduled for release on Friday, October 2nd, PAOG Jim DiPrima will highlight a new pharmaceutical cannabis research expert resource engaged by the company to bring new industry recognized expertise to move PAOG's cannabis pharmaceutical asset forward.
On July 30, 2020, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a cannabis treatment under development for COPD derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT."
In an initial scientific evaluation as a treatment for COPD, RespRx has demonstrated effecting significant increases in respiration rate, tidal volume and inspiratory air flow rate. Overall data from the evaluation demonstrated that RespRx can significantly improve inspiratory lung functions in instances of moderate pulmonary fibrosis.
With RespRx now in house, PAOG has engaged multiple new experts from both the university and commercial medical research community to evaluate the RespRx formula, the formulation process and the test results.
The expert evaluation has reviewed RespRx in conjunction with other publicly available cannabis treatment research. Two studies in particular, both of which highlight the research behind GW Pharmaceuticals' cannabinoid treatments, shed light on PAOG's wider opportunity stemming from RespRx, the process to derive RespRx and the clinical trials to date behind RespRx.
One of the two studies is focused on CBD and the other on THC. The research seems to indicate CBD has both an impact on hyper-immune responses that might result in conditions like a cytokine storm which impacts many COVID-19 patients, and positive stimulation of immune responses that fight bad cells. The THC report seems to validate its ability to relieve pain, but it also indicates immune response manipulation capabilities to include anti-inflammatory reactions and the stimulation of immune responses to fight bad cells.
In summary, existing publicly available cannabis treatment research further supports the research findings behind RespRx, and at the same time, the publicly available research sheds light on the expanded potential of PAOG's RespRx overall technology.
Market Data 
Markets 
AI
